64th ASH Annual Meeting and Exposition: 401. Blood Transfusion: Molecular Mechanisms and Novel Therapies

Symposia: Blood Transfusion Oral and Poster Abstracts
Oral

Research, Fundamental Science, clinical trials, Sickle Cell Disease, autoimmune disorders, Translational Research, Clinical Practice (Health Services and Quality), Bone Marrow Failure Syndromes, Clinical Research, Aplastic Anemia, health outcomes research, Hemoglobinopathies, drug development, patient-reported outcomes, immune mechanism, Diseases, SARS-CoV-2/COVID-19, immunology, Therapies, Infectious Diseases, real-world evidence, Adverse Events, Biological Processes

393-396 (Ernest N. Morial Convention Center)

Moderators:

Zoe McQuilten, MBBS, PhD, and Krystalyn E Hudson,

Disclosures:

McQuilten: Amgen: Research Funding; Beigene: Research Funding; Abbvie: Research Funding; GSK: Research Funding; Novartis: Research Funding; Takeda: Research Funding; BMS/Celgene: Research Funding; CSL: Research Funding; Sanofi: Research Funding; Janssen: Research Funding.

The oral session will discuss patient-related outcomes of a randomized clinical trial of a novel complement inhibitor for treatment of cold agglutinin disease (-this is being proposed for a Plenary abstract). Mechanistic studies to understand factors affecting alloimmunization versus immune suppression using mouse models will be presented and risk factors associated with platelet transfusion driven HLA alloimmunization in patients with aplastic anemia discussed. Focusing on structural similarities between receptor binding domain (RBD) of SARS-CoV-2 and carbohydrate binding proteins that recognize ABO(H) blood group antigens, experimental studies providing support for the proposed increased risk of COVID-19 infection in blood group A individuals are described. Finally, results of a prospective study of red blood cell transfusion threshold in AML patients will be presented.

9:30 AM

Sutimlimab Provides Sustained Improvements in Patient-Reported Outcomes and Quality of Life in Patients with Cold Agglutinin Disease: Open-Label Extension of the Randomized, Phase 3 Cadenza Study

Alexander Roeth, MD¹, Catherine M. Broome, MD², Wilma Barcellini, MD³^*, Bernd Jilma⁴, Quentin A. Hill⁵^*, David Cella⁶^*, Tor Henrik Anderson Tvedt⁷^*, Masaki Yamaguchi⁸^*, Irina Murakhovskaya, MD⁹, Michelle Lee, MD¹⁰^*, Frank Shafer¹¹^*, Marek Wardecki¹²^*, Jennifer Wang¹³^*, Ronnie Yoo¹⁴^*, Jerome Msihid, MSc¹⁵^* and Ilene C. Weitz¹⁶^*

¹Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, Essen, Germany
²Division of Hematology, MedStar Georgetown University Hospital, Washington, DC
³Hematology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
⁴Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
⁵Department of Clinical Haematology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
⁶Department of Medical Social Sciences, Center for Patient-Centered Outcomes, Institute for Public Health and Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL
⁷Section for Hematology, Department of Medicine, Haukeland University Hospital, Bergen, Norway
⁸Ishikawa Prefectural Central Hospital, Kanazawa, Japan
⁹Division of Hematology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY
¹⁰Global Project Head, Rare Disease and Rare Blood Disorders Development, Sanofi, Bridgewater, MA
¹¹Sanofi, Bridgewater
¹²Sanofi, Warsaw, MA, Poland
¹³Sanofi, Cambridge
¹⁴Sanofi, Boston, MA
¹⁵Sanofi, Chilly-Mazarin, France
¹⁶Keck School of Medicine of USC, Los Angeles, CA

9:45 AM

Antibody-Mediated Antigen Loss Can Switch an Augmented Immune Response to Antibody-Mediated Immunosuppression

Ryan Philip Jajosky, MD^1,2^*, Jerry W. Allen, BS³^*, Patricia E Zerra, MD^4,5, Cheryl L Maier, MD, PhD⁶, Satheesh Chonat, MD⁷, Chance John Luckey⁸^*, John D. Roback, MD, PhD⁵^*, Ross M. Fasano, MD⁶^*, Cassandra D. Josephson, MD⁹, John P Manis, MD¹⁰, Li Chai, MD¹¹, Jeanne E. Hendrickson, MD¹², Krystalyn E Hudson, PhD¹³, Connie M. Arthur, PhD¹⁴ and Sean R. Stowell, MD, PhD¹⁵

¹Biconcavity Inc., Lilburn, GA
²Department of Pathology, Brigham and Women's Hospital, Boston, MA
³Yale School of Medicine, New Haven, CT
⁴Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta/Emory University School of Medicine, Atlanta, GA
⁵Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA
⁶Center for Transfusion and Cellular Therapies, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA
⁷Emory University, Aflac Cancer & Blood Disorders Center of Children’s Healthcare of Atlanta, Atlanta, GA
⁸Department of Pathology, University of Virginia, Charlottesville, VA
⁹Emory University, Atlanta, GA
¹⁰Children's Hospital Boston, Boston, MA
¹¹Brigham and Women's Hospital, Boston, MA
¹²Department of Laboratory Medicine and Pathology, Emory University, Atlanta, GA
¹³Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY
¹⁴Joint Program in Transfusion Medicine, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
¹⁵Joint Program in Transfusion Medicine, Brigham and Women's Hospital, Boston, MA

10:00 AM

Reticulocytes Are an Unappreciated Risk Factor for RBC Alloimmunization at the Donor and Recipient Levels

Tiffany Thomas, PhD¹^*, Annie Qiu, B.S.²^*, Christopher Y Kim³^*, Dominique E Gordy⁴^*, Anabel Miller⁵^*, Maria Tredicine⁶^*, Elizabeth Stone⁴^*, Monika Dzieciatkowska⁷^*, Eldad A. Hod, MD², Angelo D'Alessandro, PhD^8,9, Steven L Spitalnik, PhD²^*, James C Zimring, MD¹⁰^*, Imo J Akpan¹¹^*, Chance John Luckey¹⁰^* and Krystalyn E Hudson, PhD²

¹Department of Pathology and Laboratory Medicine, Columbia University Irving Medical Center, New York, NY
²Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY
³Columbia University Irving Medical Center, New York, NY
⁴Columbia University Irving Medical Center, New York, NY, USA, New York, NY
⁵Department of Ptahology and Cell Biology, Columbia University Irving Medical Center, New York, NY
⁶Università Cattolica del Sacro Cuore, Rome, Italy
⁷University of Colorado Denver – Anschutz Medical Campus, Aurora
⁸Department of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora, CO
⁹Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, CO
¹⁰University of Virginia, Charlottesville
¹¹Columbia University Irving Medical Center, New York

10:15 AM

Predictors, Risk Factors and Outcomes of Patients with SAA with Anti-HLA Class I Antibodies Treated with Immunosuppressive Therapy

Jibran Durrani, MD¹, Leonard Chen, MD, PhD²^*, Ruba Shalhoub, MS³^*, Nu Ri Cha, MS⁴^*, Xiaoyang Ma, MS³^*, Jennifer Lotter⁵^*, Olga Rios, RN⁶^*, Colin O. Wu, PhD³^*, Willy A. Flegel, MD⁷, Neal S. Young, MD⁸, Bhavisha A. Patel, MD⁶ and Emma M. Groarke, MD⁶

¹The National Heart, Lung, and Blood Institute, National Institutes of Health, BETHESDA, MD
²Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD
³Office of Biostatistics Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
⁴Experimental Transplantation and Immunotherapy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
⁵National Institutes of Health, Bethesda, MD
⁶Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
⁷NIH Clinical Center, Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD
⁸National Institute of Health, Bethesda, MD

10:30 AM

Blood Group A Enhances SARS-CoV-2 Infection

Shang-Chuen Wu, PhD¹^*, Connie M. Arthur, PhD², Hau-Ming Jan, PhD²^*, Wilfredo F Garcia-Beltran, MD³^*, Kashyap R. Patel, PhD²^*, Matthew F. Rathgeber, MS²^*, Hans Verkerke, PhD⁴^*, Narayanaiah Cheedarla, PhD⁵^*, Ryan Philip Jajosky, MD⁶^*, Anu Paul, PhD²^*, Andrew S. Neish, MD⁵^*, John D. Roback, MD, PhD⁷^*, Cassandra D. Josephson, MD⁸, Duane R. Wesemann, MD, PhD⁹^*, Daniel Kalman, PhD⁷^*, Seth Rakoff-Nahoum, MD, PhD¹⁰^*, Richard D. Cummings, PhD¹¹ and Sean R. Stowell, MD, PhD¹²

¹Joint Program in Transfusion Medicine, Department of Pathology, Brigham and Women's Hospital, Boston, GA
²Joint Program in Transfusion Medicine, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
³Ragon Institute of MGH, MIT and Harvard, Cambridge, MA
⁴Center for Transfusion and Cellular Therapies, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA
⁵Emory university, Atlanta, GA
⁶Department of Pathology, Brigham and Women's Hospital, Boston, MA
⁷Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA
⁸Children's Healthcare of Atlanta Pathology Department, Atlanta, GA
⁹Brigham and Women's Hospital, Boston, MA
¹⁰Boston Children's Hospital, Boston, MA
¹¹Emory University School of Medicine, Boston, MA
¹²Joint Program in Transfusion Medicine, Brigham and Women's Hospital, Boston, MA

10:45 AM

A Prospective Randomized Study for Optimal Red Blood Cell Use Patients with Acute Myeloid Leukemia Receiving Dose Intensive Chemotherapy

Ja Min Byun, MD, PhD¹, Junshik Hong, MD^2,3, Dong-Yeop Shin, MD, PhD⁴^*, Youngil Koh, MD, PhD⁴, Sung-Soo Yoon, MD, PhD⁵, Inho Kim, MD, PhD⁶^* and Hyungsuk Kim, MD, PhD⁷^*

¹Seoul National University, Seoul, Korea, Republic of (South)
²Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN
³Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South)
⁴Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South)
⁵Division of Hematology/Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South)
⁶Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South)
⁷Department of Laboratory Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South)

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

401.O1.6 401. Blood Transfusion: Molecular Mechanisms and Novel Therapies